NEUP vs NKTX

Neuphoria Therapeutics Inc. vs Nkarta, Inc. — Valuation Comparison 2026

NEUP

Biotechnology
Neuphoria Therapeutics Inc.
Quality
5.4
out of 10
Value Trap
6
SAFE
Price
$5.36
Last close
Models
10/13
Active
VS

NKTX

Biotechnology
Nkarta, Inc.
Quality
4.6
out of 10
Value Trap
18
SAFE
Price
$3.30
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType NEUP Fair ValueNEUP Upside NKTX Fair ValueNKTX Upside
Bayesian DCF Intrinsic $3.75 -30.0% $0.66 -80.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.61 -88.6% $2.14 -35.3%
Dynamic NAV Asset-Based $6.53 +21.8% $2.32 -29.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NEUP vs NKTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NEUP vs NKTX — Which Stock Is More Undervalued?

NEUP scores higher with a 5.4/10 quality rating vs NKTX's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Neuphoria Therapeutics Inc. (NEUP) and Nkarta, Inc. (NKTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NEUP currently trades at $5.36 with a QOC of 5.4/10, while NKTX trades at $3.30 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).